recognition deficits

Brexpiprazole (OPC-34712) is a partial agonist of human 5-hydroxytryptamine (5-HT) 5-HT1A and dopamine D2 receptors.

Brexpiprazole HCl (OPC 34712 dihydrochloride) is a new antipsychotic drug.

Z944 is a T-type calcium channel antagonist with potential applications in pain management. In both epileptic and non-epileptic rats, Z944 disrupts prepulse inhibition. Additionally, it corrects cross-modal sensory and visual recognition memory deficits in Strasbourg genetic absence epilepsy rats. In a neuropathic pain rat model, Z944 restores cortical synchrony and thalamocortical connectivity. In the amygdala kindling model, it delays seizure progression.

PZ-1922 free base is a brain-penetrant 5-HT6R/5-HT3R antagonist with Ki values of 17 nM and 0.45 nM, respectively. It reversibly inhibits MAO-B (pIC50: 8.93). In rat novel object recognition (NOR) tests, PZ-1922 free base counteracts Scopolamine (SCOP)-induced memory deficits and prevents Aβ-induced memory decline in T-maze tests.

Choline is a vital nutrient essential for maintaining liver, neurological, hematological, and skeletal muscle balance. It serves as a precursor in the biosynthesis of membrane phospholipids, like phosphatidylcholine, which aid in cell signaling and membrane transport, and is also a precursor to the neurotransmitter acetylcholine. Choline is crucial for hepatic lipid transport. In animal studies, perinatal administration of choline (18.8 mg/kg) has been shown to enhance cognitive function impaired by prenatal alcohol exposure in rats. Additionally, choline (13 mg/animal per day) improves motor coordination and addresses behavioral issues in a mouse model of Rett syndrome, and mitigates recognition memory deficits caused by early-life iron deficiency in rats when provided in drinking water at 5 ppm. Low choline intake is linked to muscle wasting, and dietary choline (1,000 mg/kg) boosts leg and breast muscle protein content in broiler chickens.

UoS 12258 is a selective and efficient AMPA receptor positive allosteric modulator, reversing acute and subacute drug-induced deficits in rat novel object recognition, used to study cognitive disorders.

PZ-1922 (Compound 16), able to cross the blood-brain barrier, is a dual antagonist for 5-HT6R and 5-HT3R with K i values of 17 nM and 0.45 nM, respectively. It also reversibly inhibits MAO-B with a pIC50 of 8.93. Moreover, PZ-1922 mitigates scopolamine (SCOP)-induced memory deficits in rats as observed in the novel object recognition (NOR) test and hinders Aβ-induced memory impairment in the T-maze test [1].

Trofinetide, derived from the neuroprotective tripeptide Gly-Pro-Glu (an N-terminal sequence of insulin-like growth factor-1, IGF-1), shows promise in various neuroprotective models. At a concentration of 10 nM, it mitigates cell death in primary rat embryonic striatal neurons caused by okadaic acid. Additionally, Trofinetide reduces the expression of pro-inflammatory markers (IL-1β, TNF-α, IL-6, and E-selectin) in a rat model simulating neuroinflammation from penetrating ballistic-like brain injuries. In cases of brain injury induced by middle cerebral artery occlusion (MCAO), administration of Trofinetide at 30 and 60 mg/kg reduces the area of cortical and striatal infarct. Furthermore, a daily dose of 100 mg/kg reverses social recognition and contextual fear conditioning deficits, diminishes the number of dendritic spines, and decreases testicular weight gain in an fmr1-/- knockout mouse model of fragile X syndrome. Trofinetide formulations have been employed in treating Rett syndrome, highlighting its versatility across various neurological conditions.